MILTON KEYNES, England (Nov. 14, 2007) — Consort Medical P.L.C. will restructure its Inhaled Drug Delivery business following a decision by Pfizer Inc. last month to drop Exubera inhaled insulin from its portfolio.
Consort Medical, which recently changed its name from Bespak P.L.C., produced the inhaler for Pfizer.
The restructuring will involve the eventual closure and subsequent sale of Consort Medical´s Milton Keynes facility, which was developed to manufacture the inhaler device for Exubera, and the consolidation of Bespak Technologies and Device Services into one business unit at Consort Medical´s existing facility in King´s Lynn, Norfolk.
About 165 jobs will be eliminated once the consolidation is completed, a spokeswoman said. The company, a producer of a number of elastomeric products, will relocate to King´s Lynn over the next year.